L. Bengrine-lefevre

发表

[Cell cycle and molecular targets: CDK inhibition].

L. Meijer, S. Le Moulec, P. Carassou, 2012, Bulletin du cancer.

Platinum-sensitivity in metastatic colorectal cancer: towards a definition.

C. Tournigand, F. Bonnetain, A. Larsen, 2013, European journal of cancer.

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer

C. Borg, F. Ghiringhelli, Stefano Kim, 2018, World journal of clinical oncology.

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

C. Tournigand, A. Figer, F. Bidard, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG).

A. Bouvier, G. Albrand, E. Paillaud, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

V. Quipourt, S. Marilier, A. Bertaut, 2016, World journal of gastroenterology.

[Nasal septum perforation and bevacizumab].

C. Tournigand, A. de Gramont, C. Louvet, 2011, La Revue de medecine interne.

TTF-1 positivity in metastatic colorectal carcinoma: a diagnostic pitfall in transbronchial biopsy.

N. Mourra, L. Bengrine-lefevre, L. Bengrine-Lefevre, 2010, Applied immunohistochemistry & molecular morphology : AIMM.

Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years.

V. Quipourt, S. Marilier, J. Vincent, 2019, European journal of cancer.

Adherence to oral anti-cancer therapies in older patients is similar to that of younger patients

V. Quipourt, J. Blanc, Antonin Schmitt, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.

M. Ducreux, E. Baudin, P. Rougier, 2014, European journal of cancer.

Simple liquid chromatography method for the quantification of irinotecan and SN38 in sheep plasma: application to in vivo pharmacokinetics after pulmonary artery chemoembolization using drug eluting beads.

J. Pelage, A. Laurent, C. Fernandez, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice

C. Lepage, V. Jooste, V. Quipourt, 2022, Cancers.

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure

J. Vincent, F. Ghiringhelli, B. Royer, 2020, Pharmaceuticals.

Cancer awareness in atypical thrombotic microangiopathies.

D. Valla, L. Obéric, L. Galicier, 2009, The oncologist.

Impact of granulocyte colony‐stimulating factor on FOLFIRINOX‐induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach

J. Vincent, F. Ghiringhelli, Antonin Schmitt, 2020, British Journal of Clinical Pharmacology.

Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study).

M. Ducreux, E. Baudin, P. Ruszniewski, 2012 .

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.

C. Tournigand, M. Loh, P. Senet, 2014, Gastroenterology.